Prelude Capital Management, LLC Cytek Biosciences, Inc. Transaction History
Prelude Capital Management, LLC
- $1.85 Billion
- Q1 2024
A detailed history of Prelude Capital Management, LLC transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 15,800 shares of CTKB stock, worth $88,480. This represents 0.01% of its overall portfolio holdings.
Number of Shares
15,800Holding current value
$88,480% of portfolio
0.01%Shares
2 transactions
Others Institutions Holding CTKB
# of Institutions
121Shares Held
72.5MCall Options Held
13.2KPut Options Held
31.2K-
Black Rock Inc. New York, NY17.4MShares$97.6 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD12MShares$67.3 Million1.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$67.3 Million0.0% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.66MShares$37.3 Million0.99% of portfolio
-
State Street Corp Boston, MA4.12MShares$23 Million0.0% of portfolio
About Cytek Biosciences, Inc.
- Ticker CTKB
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 134,627,008
- Market Cap $754M
- Description
- Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...